29Jul 2022
Systematic exploration of the underlying mechanism of gemcitabine resistance in pancreatic adenocarcinoma

Systematic exploration of the underlying mechanism of gemcitabine resistance in pancreatic adenocarcinoma

Using within‐sample relative expression ordering of pairwise genes, we developed a qualitative gemcitabine signature containing 28 gene pairs named 28‐GPS. The 28‐GPS outperformed previous signatures in classification accuracy and prognostic performance for pancreatic ductal adenocarcinoma (PDAC). Compared with gemcitabine‐sensitive PDAC samples, gemcitabine‐resistant PDAC samples classified by 28‐GPS showed poorer overall survival, higher genomic instability, lower immune infiltration, higher metabolic level and higher‐fidelity DNA damage repair.

  • #oncology

Like

Save

Share